A Decision Support System for Supporting Strategic Production Allocation in the Automotive Industry

This paper deals with the optimization problem faced by the manufacturing engineering department of an international automotive company, concerning its supply chain design (i.e., decisions regarding which plants to open, how many components to produce, and the logistic flow from production to assembly plants). The intrinsic characteristics of the problem, such as stochasticity, the high number of products and components, and exogenous factors, make it complex to formulate and solve the mathematical models. Thus, new decision support systems integrating human choices and fast solution algorithms are needed. In this paper, we present an innovative and successful use case of such an approach, encompassing the decision-maker as an integral part of the optimization process. Moreover, the proposed approach allows the managers to conduct what-if analyses in real-time, taking robust decisions with respect to future scenarios, while shortening the time needed. As a byproduct, the proposed methodology requires neither the definition of a probability distribution nor the investigation of the user’s risk aversion

Towards specification of a software architecture for cross-sectoral big data applications

The proliferation of Big Data applications puts pressure on improving and optimizing the handling of diverse datasets across different domains. Among several challenges, major difficulties arise in data-sensitive domains like banking, telecommunications, etc., where strict regulations make very difficult to upload and experiment with real data on external cloud resources. In addition, most Big Data research and development efforts aim to address the needs of IT experts, while Big Data analytics tools remain unavailable to non-expert users to a large extent. In this paper, we report on the work-in-progress carried out in the context of the H2020 project I-BiDaaS (Industrial-Driven Big Data as a Self-service Solution) which aims to address the above challenges. The project will design and develop a novel architecture stack that can be easily configured and adjusted to address cross-sectoral needs, helping to resolve data privacy barriers in sensitive domains, and at the same time being usable by non-experts. This paper discusses and motivates the need for Big Data as a self-service, reviews the relevant literature, and identifies gaps with respect to the challenges described above. We then present the I-BiDaaS paradigm for Big Data as a self-service, position it in the context of existing references, and report on initial work towards the conceptual specification of the I-BiDaaS software architecture.This work is supported by the IBiDaaS project, funded by the European Commission under Grant Agreement No. 780787.Peer ReviewedPostprint (author's final draft

Digital manufacturing applicability of a laser sintered component for automotive industry: A case study

Purpose - Additive manufacturing requires a systemic approach to help industry on technology applicability research. Towards this end, the purpose of this research is to help manufacturing business Ieaders decide whether digitalised manufacturing based on additive manufacturing are suitable for engineering applications and help them plan technology transfer decisions. Design/methodology/approach - The methodology is based on case study research and action research, involving a mix of quantitative and qualitative research methods. The empirical part involved the study of the fatigue life of industrial component manufactured by Iaser sintering as well as a combination of quantitative and qualitative methods to define a strategic decision-making. Findings - Laser-sintered plastic materials are suitable in end use automotive applications, especially when there are multiple product variations. Fatigue life of the tested coupling meets the design requirements. Additionally, production of mechanical parts can be substituted by additive methods while digitalising the manufacturing process to gain productivity, especially when there is a need for mass-customisation. Research limitations/limplications- This research relies on a single case study research. The application used is unique and its technical empirical data cannot be transferred directly to other applications. Practical implications - lndustry practitioners can use this research to shed light on technology transferability challenges considering technical feasibility of additive polymer materials, economic aspects as well as strategic implications for implementing digitalised manufacturing methods based on additive manufacturing. Originality/value- This research presents a combined study of technical and strategic factors for additive manufacturing transferability using an industrial mass-customisation case as an example. ln addition, a new cost comparison model is presented including the impact of geometry variations

Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI) : a phase 3, placebo-controlled, randomised trial

Background: Patients with stable coronary artery disease and diabetes with previous percutaneous coronary intervention (PCI), particularly those with previous stenting, are at high risk of ischaemic events. These patients are generally treated with aspirin. In this trial, we aimed to investigate if these patients would benefit from treatment with aspirin plus ticagrelor. Methods: The Effect of Ticagrelor on Health Outcomes in diabEtes Mellitus patients Intervention Study (THEMIS) was a phase 3 randomised, double-blinded, placebo-controlled trial, done in 1315 sites in 42 countries. Patients were eligible if 50 years or older, with type 2 diabetes, receiving anti-hyperglycaemic drugs for at least 6 months, with stable coronary artery disease, and one of three other mutually non-exclusive criteria: a history of previous PCI or of coronary artery bypass grafting, or documentation of angiographic stenosis of 50% or more in at least one coronary artery. Eligible patients were randomly assigned (1:1) to either ticagrelor or placebo, by use of an interactive voice-response or web-response system. The THEMIS-PCI trial comprised a prespecified subgroup of patients with previous PCI. The primary efficacy outcome was a composite of cardiovascular death, myocardial infarction, or stroke (measured in the intention-to-treat population). Findings: Between Feb 17, 2014, and May 24, 2016, 11 154 patients (58% of the overall THEMIS trial) with a history of previous PCI were enrolled in the THEMIS-PCI trial. Median follow-up was 3·3 years (IQR 2·8–3·8). In the previous PCI group, fewer patients receiving ticagrelor had a primary efficacy outcome event than in the placebo group (404 [7·3%] of 5558 vs 480 [8·6%] of 5596; HR 0·85 [95% CI 0·74–0·97], p=0·013). The same effect was not observed in patients without PCI (p=0·76, p interaction=0·16). The proportion of patients with cardiovascular death was similar in both treatment groups (174 [3·1%] with ticagrelor vs 183 (3·3%) with placebo; HR 0·96 [95% CI 0·78–1·18], p=0·68), as well as all-cause death (282 [5·1%] vs 323 [5·8%]; 0·88 [0·75–1·03], p=0·11). TIMI major bleeding occurred in 111 (2·0%) of 5536 patients receiving ticagrelor and 62 (1·1%) of 5564 patients receiving placebo (HR 2·03 [95% CI 1·48–2·76], p<0·0001), and fatal bleeding in 6 (0·1%) of 5536 patients with ticagrelor and 6 (0·1%) of 5564 with placebo (1·13 [0·36–3·50], p=0·83). Intracranial haemorrhage occurred in 33 (0·6%) and 31 (0·6%) patients (1·21 [0·74–1·97], p=0·45). Ticagrelor improved net clinical benefit: 519/5558 (9·3%) versus 617/5596 (11·0%), HR=0·85, 95% CI 0·75–0·95, p=0·005, in contrast to patients without PCI where it did not, p interaction=0·012. Benefit was present irrespective of time from most recent PCI. Interpretation: In patients with diabetes, stable coronary artery disease, and previous PCI, ticagrelor added to aspirin reduced cardiovascular death, myocardial infarction, and stroke, although with increased major bleeding. In that large, easily identified population, ticagrelor provided a favourable net clinical benefit (more than in patients without history of PCI). This effect shows that long-term therapy with ticagrelor in addition to aspirin should be considered in patients with diabetes and a history of PCI who have tolerated antiplatelet therapy, have high ischaemic risk, and low bleeding risk